Therapeutic Asset Ratings

143 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Karxt Alzheimer Disease	Bristol-Myers Squibb	P3	CCC (52)
Autologous Cd34+ Cells Transduced With Tns9.3.55 Sickle Cell Disease	Daniel Bauer	P2	CCC (52)
Tas-102 Colon Carcinoma	Rutgers, The State University of New Jersey	P2	CCC (52)
Tas-102 Pancreatic Neoplasm	National Cancer Institute (NCI)	P2	CCC (52)
Tas-102 Endometrial Cancer	National Cancer Institute (NCI)	P2	CCC (51)
Tas-102 Glioma	National Cancer Institute (NCI)	P2	CCC (51)
Tas-102 Immunotherapy	Fujian Cancer Hospital	P2	CCC (51)
Autologous Cd34+ Cells Transduced With Tns9.3.55 Beta Thalassemia	Daniel Bauer	P1/2	CCC (50)
Nalirifox Pancreatic Ductal Adenocarcinoma	The University of Texas Health Science Center, Houston	P2	CCC (48)
Tas-102 Melanoma	National Cancer Institute (NCI)	P2	CCC (48)
Autologous Cd34+ Cells Transduced With A Lentiviral Vector Containing The Human Sgsh Gene Mucopolysaccharidosis Type 3A	University of Manchester	P1/2	CCC (48)
Autologous Cd34+ Cells Transduced With Tns9.3.55 Mucopolysaccharidosis Type 2	University of Manchester	P1/2	CCC (48)
Autologous Cd34+ Cells Transduced With Tns9.3.55 Mucopolysaccharidosis Type 3A	University of Manchester	P1/2	CCC (48)
Begev Hodgkins Lymphoma	Fondazione Italiana Linfomi - ETS	P1/2	CCC (48)
Spedox-6 Soft Tissue Sarcoma	University of California, Irvine	P1/2	CCC (48)
Trifluridine/Tipiracil Hydrochloride Combination Agent Tas-102 Anal Carcinoma	Oncolytics Biotech	P1/2	CCC (48)
Trifluridine/Tipiracil Hydrochloride Combination Agent Tas-102 Anal Squamous Cell Carcinoma	Oncolytics Biotech	P1/2	CCC (48)
Trifluridine/Tipiracil Hydrochloride Combination Agent Tas-102 Exocrine Pancreatic Carcinoma	Oncolytics Biotech	P1/2	CCC (48)
Spedox-6 KRAS Mutation-Related Tumors	University of California, Irvine	P1/2	CC (47)
bs006 Neoplasm	Binhui Biopharmaceutical Co., Ltd.	P1/2	CC (45)
Trifluridine/Tipiracil Hydrochloride Combination Agent Tas-102 Malignant Pancreatic Neoplasm	Oncolytics Biotech	P1/2	CC (45)
Actinium Ac 225-Dota-Daratumumab Plasma Cell Myeloma	City of Hope Medical Center	P1	CC (43)
Neural Stem Cells-Expressing Crad-S-Pk7 Glioblastoma	City of Hope Medical Center	P1	CC (43)
Tas-102 Advanced or Metastatic Solid Tumor	Taiho Pharmaceutical Co., Ltd.	P1	CC (43)
Tas-102 Alveolar Soft Part Sarcoma	Taiho Pharmaceutical Co., Ltd.	P1	CC (43)

Showing 101 to 125 of 143 assets

PreviousPage 5 of 6Next